Literature DB >> 9666022

In vitro testing of susceptibilities of filamentous ascomycetes to voriconazole, itraconazole, and amphotericin B, with consideration of phylogenetic implications.

M R McGinnis1, L Pasarell.   

Abstract

The in vitro susceptibilities of three hundred eighty-one isolates representing two classes, five orders, nine families, 30 genera, and 51 species of ascomycetous fungi to voriconazole, itraconazole, and amphotericin B were tested by using a modification of the National Committee for Clinical Laboratory Standards M27-A reference method. For those fungi of known phylogenetic relatedness, drug MICs were consistently low for isolates among all clades, except for members of the family Microascaceae. The highest MICs of all drugs tested were consistently for the Microascaceae, supporting the observation of fungal phylogeny and corresponding susceptibility to antifungal drugs. Itraconazole and voriconazole have a broad range of activity against phylogenetically similar agents of hyalohyphomycosis, phaeohyphomycosis, chromoblastomycosis, and mycetoma.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9666022      PMCID: PMC105048     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  7 in total

1.  In vitro evaluation of voriconazole against some clinically important fungi.

Authors:  M R McGinnis; L Pasarell; D A Sutton; A W Fothergill; C R Cooper; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

2.  Viability of fungal cultures maintained at -70 degrees C.

Authors:  L Pasarell; M R McGinnis
Journal:  J Clin Microbiol       Date:  1992-04       Impact factor: 5.948

3.  In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp.

Authors:  F Marco; M A Pfaller; S Messer; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

4.  In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens.

Authors:  A Espinel-Ingroff
Journal:  J Clin Microbiol       Date:  1998-01       Impact factor: 5.948

5.  The antigenic composition and protein profiles of eumycetoma agents.

Authors:  F Zaini; M K Moore; D Hathi; R J Hay; W C Noble
Journal:  Mycoses       Date:  1991 Jan-Feb       Impact factor: 4.377

6.  An evaluation of straw-extract agar media for the growth and sporulation of Madurella mycetomatis.

Authors:  C Rajendran; A Baby; S Kumari; T Verghese
Journal:  Mycopathologia       Date:  1991-07       Impact factor: 2.574

7.  In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species.

Authors:  A L Barry; S D Brown
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

  7 in total
  33 in total

1.  In vitro activity of Syn-2869, a novel triazole agent, against emerging and less common mold pathogens.

Authors:  E M Johnson; A Szekely; D W Warnock
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  Relapsing cutaneous alternariosis in a kidney transplant recipient cured with liposomal amphotericin B.

Authors:  E Merino; J Bañuls; V Boix; A Franco; J Guijarro; J Portilla; I Betlloch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-01-16       Impact factor: 3.267

Review 3.  Impact of melanin on microbial virulence and clinical resistance to antimicrobial compounds.

Authors:  Joshua D Nosanchuk; Arturo Casadevall
Journal:  Antimicrob Agents Chemother       Date:  2006-11       Impact factor: 5.191

Review 4.  Dual Invasive Infection with Phaeoacremonium parasiticum and Paraconiothyrium cyclothyrioides in a Renal Transplant Recipient: Case Report and Comprehensive Review of the Literature of Phaeoacremonium Phaeohyphomycosis.

Authors:  Marie-Alice Colombier; Alexandre Alanio; Blandine Denis; Giovanna Melica; Dea Garcia-Hermoso; Bénédicte Levy; Marie-Noëlle Peraldi; Denis Glotz; Stéphane Bretagne; Sébastien Gallien
Journal:  J Clin Microbiol       Date:  2015-04-22       Impact factor: 5.948

5.  In vitro evaluation of the type of interaction obtained by the combination of terbinafine and itraconazole, voriconazole, or amphotericin B against dematiaceous molds.

Authors:  Fernanda Simas Corrêa Biancalana; Luzia Lyra; Angélica Zaninelli Schreiber
Journal:  Antimicrob Agents Chemother       Date:  2011-06-20       Impact factor: 5.191

6.  Ochroconis calidifluminalis, a sibling of the neurotropic pathogen O. gallopava, isolated from hot spring.

Authors:  Kyoko Yarita; Ayako Sano; Kittipan Samerpitak; Katsuhiko Kamei; G Sybren de Hoog; Kazuko Nishimura
Journal:  Mycopathologia       Date:  2010-03-07       Impact factor: 2.574

7.  Subcutaneous fungal infections.

Authors:  Ricardo M La Hoz; John W Baddley
Journal:  Curr Infect Dis Rep       Date:  2012-10       Impact factor: 3.725

8.  In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi.

Authors:  A Espinel-Ingroff
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

9.  In vitro susceptibility of environmental isolates of Exophiala dermatitidis to five antifungal drugs.

Authors:  Ana Paula Miranda Duarte; Fernando Carlos Pagnocca; Noemi Carla Baron; Marcia de Souza Carvalho Melhem; Gislene Aparecida Palmeira; Dejanira de Franceschi de Angelis; Derlene Attili-Angelis
Journal:  Mycopathologia       Date:  2012-11-16       Impact factor: 2.574

10.  In vitro comparison of activities of terbinafine and itraconazole against Paracoccidioides brasiliensis.

Authors:  R C Hahn; C J F Fontes; R D Batista; J S Hamdan
Journal:  J Clin Microbiol       Date:  2002-08       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.